First-ever brain chemistry database will allow clinicians to quickly infer brain biomarker data to support the diagnostic process in conditions such as Alzheimer's Disease
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Evinova will operate as a separate health-tech business within AstraZeneca
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain
XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer
Phase 3 data expected in the second half of 2024
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
In 2022, darolutamide was FDA-approved in combination with docetaxel chemotherapy for adults with metastatic hormone-sensitive prostate cancer
Subscribe To Our Newsletter & Stay Updated
